Welcome to LookChem.com Sign In|Join Free

CAS

  • or

191469-29-1

Post Buying Request

191469-29-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • Benzoic acid, 2,6-difluoro-4-[[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbonyl]amino]-

    Cas No: 191469-29-1

  • No Data

  • No Data

  • No Data

  • BOC Sciences
  • Contact Supplier

191469-29-1 Usage

General Description

AGN 195183, also known as bimatoprost, is a prostaglandin analogue used for the treatment of glaucoma and ocular hypertension. It works by decreasing intraocular pressure in the eye, which can help to prevent optic nerve damage and potential vision loss. AGN 195183 is available in the form of eye drops, and is typically used once daily. It is considered to be a safe and effective treatment for these eye conditions, and is well-tolerated by most patients. However, it may cause some side effects, such as eye redness, itching, and darkening of the eyelids or eye color. Overall, AGN 195183 is an important medication for managing glaucoma and ocular hypertension.

Check Digit Verification of cas no

The CAS Registry Mumber 191469-29-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,1,4,6 and 9 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 191469-29:
(8*1)+(7*9)+(6*1)+(5*4)+(4*6)+(3*9)+(2*2)+(1*9)=161
161 % 10 = 1
So 191469-29-1 is a valid CAS Registry Number.

191469-29-1Downstream Products

191469-29-1Relevant articles and documents

Synthesis and biological activity of retinoic acid receptor-α specific amides

Beard, Richard L.,Duong, Tien T.,Teng, Min,Klein, Elliott S.,Standevan, Andrew M.,Chandraratna, Roshantha A.S.

, p. 3145 - 3148 (2002)

Retinoids are analogues of all-trans-retinoic acid, a powerful hormone that mediates many fundamental biological processes. Cancer and other serious hyperproliferative diseases are attractive therapeutic targets for retinoids, but the therapeutic use of retinoids is limited due to severe toxicity. We report here the design of retinoid receptor-α specific ligands with growth inhibitory activity in breast cancer cell lines, and which do not cause the cutaneous toxicity associated with the currently available nonselective retinoid agonists.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 191469-29-1